From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
During the last decades, the use of nanotechnology in medicine has effectively been translated to the design of drug delivery systems, nanostructured tissues, diagnostic platforms, and novel nanomaterials against several human diseases and infectious pathogens. Nanotechnology-enabled vaccines have b...
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Springer Singapore
2022
|
| Online Access: | https://hdl.handle.net/1721.1/138853 |
| _version_ | 1811097132783894528 |
|---|---|
| author | Lopez-Cantu, Diana O. Wang, Xichi Carrasco-Magallanes, Hector Afewerki, Samson Zhang, Xingcai Bonventre, Joseph V. Ruiz-Esparza, Guillermo U. |
| author2 | Harvard University--MIT Division of Health Sciences and Technology |
| author_facet | Harvard University--MIT Division of Health Sciences and Technology Lopez-Cantu, Diana O. Wang, Xichi Carrasco-Magallanes, Hector Afewerki, Samson Zhang, Xingcai Bonventre, Joseph V. Ruiz-Esparza, Guillermo U. |
| author_sort | Lopez-Cantu, Diana O. |
| collection | MIT |
| description | During the last decades, the use of nanotechnology in medicine has effectively been translated to the design of drug delivery systems, nanostructured tissues, diagnostic platforms, and novel nanomaterials against several human diseases and infectious pathogens. Nanotechnology-enabled vaccines have been positioned as solutions to mitigate the pandemic outbreak caused by the novel pathogen severe acute respiratory syndrome coronavirus 2. To fast-track the development of vaccines, unprecedented industrial and academic collaborations emerged around the world, resulting in the clinical translation of effective vaccines in less than one year. In this article, we provide an overview of the path to translation from the bench to the clinic of nanotechnology-enabled messenger ribonucleic acid vaccines and examine in detail the types of delivery systems used, their mechanisms of action, obtained results during each phase of their clinical development and their regulatory approval process. We also analyze how nanotechnology is impacting global health and economy during the COVID-19 pandemic and beyond. |
| first_indexed | 2024-09-23T16:54:51Z |
| format | Article |
| id | mit-1721.1/138853 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T16:54:51Z |
| publishDate | 2022 |
| publisher | Springer Singapore |
| record_format | dspace |
| spelling | mit-1721.1/1388532024-06-07T20:19:50Z From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines Lopez-Cantu, Diana O. Wang, Xichi Carrasco-Magallanes, Hector Afewerki, Samson Zhang, Xingcai Bonventre, Joseph V. Ruiz-Esparza, Guillermo U. Harvard University--MIT Division of Health Sciences and Technology Massachusetts Institute of Technology. School of Engineering During the last decades, the use of nanotechnology in medicine has effectively been translated to the design of drug delivery systems, nanostructured tissues, diagnostic platforms, and novel nanomaterials against several human diseases and infectious pathogens. Nanotechnology-enabled vaccines have been positioned as solutions to mitigate the pandemic outbreak caused by the novel pathogen severe acute respiratory syndrome coronavirus 2. To fast-track the development of vaccines, unprecedented industrial and academic collaborations emerged around the world, resulting in the clinical translation of effective vaccines in less than one year. In this article, we provide an overview of the path to translation from the bench to the clinic of nanotechnology-enabled messenger ribonucleic acid vaccines and examine in detail the types of delivery systems used, their mechanisms of action, obtained results during each phase of their clinical development and their regulatory approval process. We also analyze how nanotechnology is impacting global health and economy during the COVID-19 pandemic and beyond. 2022-01-10T13:46:07Z 2022-01-10T13:46:07Z 2022-01-03 2022-01-09T04:10:02Z Article http://purl.org/eprint/type/JournalArticle 2150-5551 2311-6706 https://hdl.handle.net/1721.1/138853 Lopez-Cantu, D.O., Wang, X., Carrasco-Magallanes, H. et al. From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nano-Micro Lett. 14, 41 (2022) en https://doi.org/10.1007/s40820-021-00771-8 Nano-Micro Letters Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ The Author(s) application/pdf Springer Singapore Springer Singapore |
| spellingShingle | Lopez-Cantu, Diana O. Wang, Xichi Carrasco-Magallanes, Hector Afewerki, Samson Zhang, Xingcai Bonventre, Joseph V. Ruiz-Esparza, Guillermo U. From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines |
| title | From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines |
| title_full | From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines |
| title_fullStr | From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines |
| title_full_unstemmed | From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines |
| title_short | From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines |
| title_sort | from bench to the clinic the path to translation of nanotechnology enabled mrna sars cov 2 vaccines |
| url | https://hdl.handle.net/1721.1/138853 |
| work_keys_str_mv | AT lopezcantudianao frombenchtotheclinicthepathtotranslationofnanotechnologyenabledmrnasarscov2vaccines AT wangxichi frombenchtotheclinicthepathtotranslationofnanotechnologyenabledmrnasarscov2vaccines AT carrascomagallaneshector frombenchtotheclinicthepathtotranslationofnanotechnologyenabledmrnasarscov2vaccines AT afewerkisamson frombenchtotheclinicthepathtotranslationofnanotechnologyenabledmrnasarscov2vaccines AT zhangxingcai frombenchtotheclinicthepathtotranslationofnanotechnologyenabledmrnasarscov2vaccines AT bonventrejosephv frombenchtotheclinicthepathtotranslationofnanotechnologyenabledmrnasarscov2vaccines AT ruizesparzaguillermou frombenchtotheclinicthepathtotranslationofnanotechnologyenabledmrnasarscov2vaccines |